JP2021522303A5 - - Google Patents

Info

Publication number
JP2021522303A5
JP2021522303A5 JP2020561788A JP2020561788A JP2021522303A5 JP 2021522303 A5 JP2021522303 A5 JP 2021522303A5 JP 2020561788 A JP2020561788 A JP 2020561788A JP 2020561788 A JP2020561788 A JP 2020561788A JP 2021522303 A5 JP2021522303 A5 JP 2021522303A5
Authority
JP
Japan
Prior art keywords
region
substitution
sequence shown
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522303A (ja
JP7649139B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/061455 external-priority patent/WO2019211472A1/en
Publication of JP2021522303A publication Critical patent/JP2021522303A/ja
Publication of JP2021522303A5 publication Critical patent/JP2021522303A5/ja
Priority to JP2025035978A priority Critical patent/JP2025085008A/ja
Application granted granted Critical
Publication of JP7649139B2 publication Critical patent/JP7649139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561788A 2018-05-03 2019-05-03 抗体バリアントの組み合わせおよびその使用 Active JP7649139B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025035978A JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201800195 2018-05-03
DKPA201800195 2018-05-03
DKPA201800644 2018-09-26
DKPA201800644 2018-09-26
PCT/EP2019/061455 WO2019211472A1 (en) 2018-05-03 2019-05-03 Antibody variant combinations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025035978A Division JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Publications (3)

Publication Number Publication Date
JP2021522303A JP2021522303A (ja) 2021-08-30
JP2021522303A5 true JP2021522303A5 (cg-RX-API-DMAC7.html) 2022-05-13
JP7649139B2 JP7649139B2 (ja) 2025-03-19

Family

ID=66476613

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561788A Active JP7649139B2 (ja) 2018-05-03 2019-05-03 抗体バリアントの組み合わせおよびその使用
JP2025035978A Pending JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025035978A Pending JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Country Status (14)

Country Link
US (2) US12338289B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788074A1 (cg-RX-API-DMAC7.html)
JP (2) JP7649139B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210008380A (cg-RX-API-DMAC7.html)
CN (1) CN112839958A (cg-RX-API-DMAC7.html)
AU (2) AU2019264217B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098486A1 (cg-RX-API-DMAC7.html)
IL (1) IL278338B1 (cg-RX-API-DMAC7.html)
MA (1) MA52485A (cg-RX-API-DMAC7.html)
MX (1) MX2020011552A (cg-RX-API-DMAC7.html)
PH (1) PH12020551808A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010601VA (cg-RX-API-DMAC7.html)
WO (1) WO2019211472A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
US12649798B2 (en) 2018-01-24 2026-06-09 Genmab B.V. Polypeptide variants and uses thereof
JP7880817B2 (ja) 2019-11-06 2026-06-26 ジェンマブ ビー.ブイ. 抗体変種の組み合わせおよびその使用
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
JP2023522027A (ja) * 2020-04-17 2023-05-26 ヤンセン バイオテツク,インコーポレーテツド 生合成糖タンパク質集団
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
KR20230156921A (ko) * 2021-03-12 2023-11-15 젠맵 에이/에스 비-활성화 항체 변이체
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20250230254A1 (en) * 2021-10-20 2025-07-17 Janssen Biotech, Inc. Biosynthetic bioparatopic or bispecific binding molecules with enhanced effector functions
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8679500B2 (en) 2009-05-14 2014-03-25 Institute National De La Sante Et De La Recherche Medicale (Inserm) Compositions containing antibodies for treating CD5+ HLA-DR+ B or T cell related diseases
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
MX387324B (es) * 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
JP2017513481A (ja) 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Fcタンパク質
MX2017012805A (es) * 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
CN108779182A (zh) * 2015-12-28 2018-11-09 麻省理工学院 具有恒定区突变的双特异性抗体及其用途
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
CN119285787A (zh) 2017-03-31 2025-01-10 健玛保控股有限公司 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
JP7880817B2 (ja) 2019-11-06 2026-06-26 ジェンマブ ビー.ブイ. 抗体変種の組み合わせおよびその使用

Similar Documents

Publication Publication Date Title
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
US11202828B2 (en) Therapeutic SIRP-α antibodies
ES2460517T3 (es) Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
CN113454119B (zh) 抗btla抗体
CN111484555B (zh) 新型双特异性cd3/cd20多肽复合物
EP4249066A2 (en) Antibodies to tigit
CN109862910A (zh) 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
JP2019503363A (ja) 急性リンパ芽球性白血病を治療するための二重特異性の抗cd20/抗cd3抗体
CN114456272A (zh) 靶向afp肽/mhc复合体的构建体及其用途
JP2022538718A (ja) 二重特異性抗体及びその調製方法、使用
JP2025085008A (ja) 抗体バリアントの組み合わせおよびその使用
JP2020516309A5 (cg-RX-API-DMAC7.html)
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP7486616B2 (ja) Btla抗体
KR20250024104A (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
AU2022278013A1 (en) Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
CN112292399A (zh) 抗cd27抗体及其用途
TWI889761B (zh) Cd137結合分子及其用途
JP2022517216A5 (cg-RX-API-DMAC7.html)
JP2024534116A5 (cg-RX-API-DMAC7.html)
JP2023500701A5 (cg-RX-API-DMAC7.html)
JP2021528439A5 (cg-RX-API-DMAC7.html)
CN117460747A (zh) 靶向CD79b、CD20和CD3的三特异性抗体
CN113975385A (zh) 新型双特异性抗cd3/cd20多肽复合物配制剂
Gupta et al. Therapeutic human monoclonal antibodies